Published in Nervenarzt on November 01, 2007
Varying uses of anticonvulsant medications. Psychiatry (Edgmont) (2008) 0.85
SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry (2004) 1.60
Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry (2002) 1.49
Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev (2004) 1.41
[Core symptoms of depression. Effectiveness of antidepressant therapy]. Nervenarzt (2009) 1.40
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry (2008) 1.20
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett (2001) 1.20
Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis (2006) 1.15
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Dizziness in an older community dwelling population: a multifactorial syndrome. J Nutr Health Aging (2009) 1.07
Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol (1999) 1.07
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J (2003) 1.06
Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry (2006) 1.04
Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron (1994) 1.04
The SIMA-project: effects of 1 year cognitive and psychomotor training on cognitive abilities of the elderly. Behav Brain Res (1996) 1.03
Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol (1999) 1.03
Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry (1999) 1.01
Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol (1992) 1.01
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett (2001) 1.01
Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience (2011) 1.00
Progesterone-induced changes in sleep in male subjects. Am J Physiol (1997) 1.00
Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther (1997) 0.98
Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry (2003) 0.95
Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol (2012) 0.94
The frailty syndrome in general practitioner care: a pilot study. Z Gerontol Geriatr (2010) 0.93
Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol (1998) 0.93
Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry (2004) 0.93
Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology (1999) 0.91
Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. J Neuroendocrinol (2012) 0.91
Neuroactive steroids as modulators of depression and anxiety. Neuroscience (2005) 0.91
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry (2000) 0.91
Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology (2001) 0.89
Alpha-thujone reduces 5-HT3 receptor activity by an effect on the agonist-reduced desensitization. Neuropharmacology (2004) 0.89
Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol (1998) 0.88
Predictors for occasional and recurrent falls in community-dwelling older people. Z Gerontol Geriatr (2009) 0.87
Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis. J Clin Invest (1996) 0.87
Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry (2006) 0.85
Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res (2000) 0.85
Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases. Curr Neuropharmacol (2013) 0.85
The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology (2001) 0.84
Impact of gene-gender effects of adrenergic polymorphisms on hypothalamic-pituitary-adrenal axis activity in depressed patients. Neuropsychobiology (2008) 0.83
Flunitrazepam has an inverse agonistic effect on recombinant alpha6beta2gamma2-GABAA receptors via a flunitrazepam-binding site. J Biol Chem (1997) 0.83
Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology (2003) 0.82
Haloperidol-induced cell death--mechanism and protection with vitamin E in vitro. Neuroreport (1995) 0.82
Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonists. J Clin Endocrinol Metab (1990) 0.82
Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry (2001) 0.82
Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry (2001) 0.82
Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry (1989) 0.81
Physical stress-induced secretion of adrenal and pituitary hormones in patients with atopic eczema compared with normal controls. Exp Clin Endocrinol Diabetes (1997) 0.81
Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet (2000) 0.80
Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder. J Affect Disord (1992) 0.80
To live alone and to be depressed, an alarming combination for the renin-angiotensin-aldosterone-system (RAAS). Psychoneuroendocrinology (2011) 0.80
Assessment of cognitive performance after progesterone administration in healthy male volunteers. Neuropsychobiology (1997) 0.80
Neuroactive steroids and affective disorders. Pharmacol Biochem Behav (2006) 0.80
The GABA(A) receptor antagonist picrotoxin attenuates most sleep changes induced by progesterone. Psychopharmacology (Berl) (1999) 0.80
Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy. Arch Neurol (2001) 0.79
Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology (2000) 0.79
Sleep disturbances and depressed mood: a harmful combination associated with increased leptin levels in women with normal weight. Biol Psychol (2011) 0.79
Endocrine responses to growth hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone in depression. Acta Psychiatr Scand (1989) 0.79
Repetitive transcranial magnetic stimulation induces active coping strategies and attenuates the neuroendocrine stress response in rats. J Psychiatr Res (2001) 0.78
[Non-medicamentous therapy and prevention of Alzheimer disease]. Z Gerontol Geriatr (2001) 0.78
Functional properties of deoxycorticosterone and spironolactone: molecular characterization and effects on sleep-endocrine activity. J Psychiatr Res (1994) 0.78
Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand (1988) 0.78
Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry (2009) 0.78
Po gene expression is modulated by androgens in the sciatic nerve of adult male rats. Brain Res Mol Brain Res (1999) 0.78
Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. Brain Res (1993) 0.78
Multihormonal response to dexamethasone. A study in atopic dermatitis and normal controls. Acta Derm Venereol (1991) 0.78
Elevated glucocorticoid receptor concentrations before and after glucocorticoid therapy in peripheral mononuclear leukocytes of patients with atopic dermatitis. Dermatologica (1991) 0.78
Endocrine responses to growth hormone releasing hormone and corticotropin releasing hormone in early-onset Alzheimer's disease. Psychiatry Res (1990) 0.78
Social isolation and depressed mood are associated with elevated serum leptin levels in men but not in women. Psychoneuroendocrinology (2010) 0.77
The combined dexamethasone-CRH test before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychoneuroendocrinology (2003) 0.77
[Cognitive effects of combined memory and psychomotor training in elderly adults]. Rev Neurol (2008) 0.77
Independent component analysis applied to pharmacological magnetic resonance imaging (phMRI): new insights into the functional networks underlying panic attacks as induced by CCK-4. Curr Pharm Des (2008) 0.77
Marijuana precipitation of panic disorder with agoraphobia. Acta Psychiatr Scand (1998) 0.77
[Vibration signals during mating of Panorpa (Mecoptera, Insecta)]. Experientia (1974) 0.77
Pharmacological characterisation of cortical gamma-aminobutyric acid type A (GABAA) receptors in two Wistar rat lines selectively bred for high and low anxiety-related behaviour. World J Biol Psychiatry (2000) 0.77
Neuroactive steroids are not affected by panic induction with 50 microg cholecystokinin-tetrapeptide (CCK-4) in healthy volunteers. J Psychiatr Res (2004) 0.77
Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol (2001) 0.77
Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res (1996) 0.77
Vigabatrin and tiagabine might have antipanic properties. J Psychopharmacol (2004) 0.77
Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J Affect Disord (1991) 0.77
[New insights into the pathogenesis and pathophysiology of depression]. Nervenarzt (2007) 0.76
Cortisol, corticotropin, and beta-endorphin responses to corticotropin-releasing hormone in patients with atopic eczema. Psychoneuroendocrinology (1995) 0.76
Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocrinol Metab (2001) 0.76
Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun (1996) 0.76
[Electroconvulsive therapy at the Department of Psychiatry and Psychotherapy, University of Munich. Development during the years 1995-2002]. Nervenarzt (2005) 0.76
Allopregnanolone acts as an inhibitory modulator on alpha1- and alpha6-containing GABA-A receptors. Biochem Biophys Res Commun (1996) 0.76
Sleep endocrine effects of megestrol acetate in healthy men. J Neuroendocrinol (1998) 0.76
Modulation of ligand-gated ion channels as a novel pharmacological principle. Pharmacopsychiatry (2011) 0.75